China LSHC IndustrySurvey Result: ‘Future of Trust’China Life Sciences & Health Care TeamJanuary, 2022Content?Framework?Results - Questions & Deep-dive?Trust: Key stakeholders and their perceptions?Trust: Actions and resources to manage?Summary Insights and the future?Appendix? 2022. For information, contact Deloitte China.2021 ChCihnianLaSLHSCHCInIdnudsutsrytr–y Survey Result: ‘Future of Trust’22021 Survey for Future of Trust in China LSHC IndustryFramework? The survey was conducted from 1to 15November 2021stth? Engaged a total of 68 China based life sciences & healthcare (LSHC) operators and investors7%5%7%13%16%13%PharmaChairman/CEOChinese SOEDistributor/RetailerMedical DevicesHealthcare ServicesOthersRespondents’TypeC-Suite levelCompanyTypeChinese POEBusinessSector34%13%55%Other management levelOthers, please specifyJV with foreign investmentWOFE22%66%46%3%12%16%21%Have manufacturingfacilities in ChinaLess than RMB 50 millionLess than 5,000RMB 50 million – 500 millionRM